Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Published On: 2 June 2023

  • Martin Jönsson: “The time is ripe for a breakthrough in dementia treatment”

    Nearly 100,000 people in Sweden suffer from Alzheimer’s. Globally, about 30 million people are thought to have the disease. There is still no cure, but research is approaching a point where new drugs may become crucial. AlzeCure is one of the pharmaceutical companies that has made the most progress.

  • AlzeCure Pharma

    The stimulating environment with access to leading research in the area, and the positive climate on Campus Flemingsberg encourages exciting co-operation

  • Bactigard

    When we needed more space to establish an integrated facility for all our activities, including production, Flemingsberg was the natural choice

  • Biomedrex Genetics

    Thanks to great contacts, including Flemingsberg Science, we quickly got a place at Ana Futura in Flemingsberg.

  • Cellaviva: improving lives through stem cell technology

    Flemingsberg is a cluster for cell therapies that gives us proximity to partners, the clinical research and the trial clinic at Karolinska Hospital where many of the patients have received their treatment.